Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 131Colonic Neoplasms 72Rectal Neoplasms 61Breast Neoplasms 61Stomach Neoplasms 37Pancreatic Neoplasms 31Squamous Cell Carcinoma of Head and Neck 27Esophageal Neoplasms 24Head and Neck Neoplasms 23Neoplasm Metastasis 22Esophageal Squamous Cell Carcinoma 16Carcinoma, Hepatocellular 16Adenocarcinoma Of Esophagus 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Neoplasms 11Nasopharyngeal Carcinoma 11Adenocarcinoma 7Urinary Bladder Neoplasms 5Keratosis, Actinic 5Cholangiocarcinoma 5Anus Neoplasms 5Intestinal Neoplasms 4Inflammatory Breast Neoplasms 4Hepatoblastoma 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Biliary Tract Neoplasms 4Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3HIV Infections 3

Interventions

beta-D-glucosylisophosphoramide mustard 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Metastatic Pancreatic Adenocarcinoma × Fluorouracil × Clear all
NCT01954992 2024-12-31

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Eleison Pharmaceuticals LLC.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡